Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Psychotic major depression (PMD) is found to be a relatively common psychiatric condition that affects up to nearly 20% of patients with major depression. Previous studies by our group have shown rapid reversal of psychotic symptoms in some PMD patients treated with mifepristone, in addition to restoring a more normal afternoon cortisol release. The rationale for treating patients with PMD with a glucocorticosteroid receptor antagonist is further discussed. In total, 30 patients with PMD were treated with either 600 mg/day mifepristone or placebo for 8 days in a randomized double-blind manner. The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment. Cortisol and ACTH were measured hourly from 1800 to 0900 at baseline and after 8 days of treatment. Significantly, more patients in the mifepristone group (seven of 15) showed a 50% or greater decline on the BPRS positive symptom subscale, an index of psychotic symptoms, as compared to the placebo group (two of 15). Patients who received mifepristone had lower HDRS and BPRS scores at study completion compared to those who received placebo, but these differences were not statistically significant. In addition, mifepristone significantly elevated cortisol and ACTH levels and steepened ascending slopes from 1800 to 0100 and from 0100 to 0900 as compared to placebo. Clinical and biological effects of mifepristone were comparable among males and females. Age was found to significantly and positively correlate with changes in cortisol and ACTH. These results suggest that short-term use of mifepristone may be effective in the treatment of PMD and may re-regulate the HPA axis. Additional blinded studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…procedures included the Structured Clinical Interview for the DSM-IV (SCID; First et al, 1997), the 21-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1980), the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1961), and clinical laboratory tests (complete blood count,…”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment.”
MethodBrain corticosteroid receptor balance and homeostatic control
de Kloet, E. R. (1991) · Frontiers in Neuroendocrinology · Cited by 842
Disrupted 24-hour patterns of cortisol secretion in psychotic depression
Sachar, E. J. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750310011002 · Cited by 775 · cited 1×
“…they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundLupien, S. J., Gillin, C. J., & Hauger, R. L. (1999) · Behavioral Neuroscience · doi:10.1037/0735-7044.113.3.420 · Cited by 561 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultDecreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultFunctional biology of intestinal goblet cells
Specian, R. D., & Oliver, M. G. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.260.2.c183 · Cited by 467
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 2×
“Most notably, they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Self-citation
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM IV-TR Axis I Disorders—Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc.: Washington, DC.
Cited by
Items 101–200 of 204
van Gemert, N. G., & Joëls, M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01472.x · Cited by 38
Pariante, C. M., Alhaj, H. A., Arulnathan, V. E., Gallagher, P., Hanson, A., Massey, E., & McAllister-Williams, R. H. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.011 · Cited by 33
“This conceptualization would also be consistent with the notion that hypercortisolemia contributes to at least some depressive symptoms, and that successful antidepressant strategies involves reducing GR function, for example using the antiglucocorticoid neuroactive steroid, dehydroepiandrosterone, the cortisol synthe…”
BackgroundWang, D., Lin, W., Pan, Y., KUANG, X.-Y., Qi, X., & Sun, H. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.01.011 · Cited by 36
CRF1 Not Glucocorticoid Receptors Mediate Prepulse Inhibition Deficits in Mice Overexpressing CRF
Groenink, L., Dirks, A., Verdouw, P. M., de Graaff, M., Peeters, B. W. M. M., Millan, M. J., & Olivier, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.002 · Cited by 35
Glucocorticoids as Predictors of Treatment Response in Depression
Horstmann, S., & Binder, E. B. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586550 · Cited by 34
Emerging drugs for major depressive disorder
Kennedy, S. H., & Rizvi, S. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903107751 · Cited by 39
“Preliminary results in a small study supported the benefits of mifepristone in a 4-day double-blind placebo controlled exposure in MDD patients with psychotic features [89] and a subsequent RCT confirmed antipsychotic but not antidepressant benefits for mifespristone [138].”
ResultGlucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats
Lou, Y.-X., Li, J., Wang, Z., Xia, C., & Chen, N. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4936-2 · Cited by 37
McCutcheon, J. E., Fisher, A. S., Guzdar, E., Wood, S. A., Lightman, S. L., & Hunt, S. P. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06043.x · Cited by 33
Ambrogio, A. G., Giraldi, F. P., & Cavagnini, F. (2008) · Pituitary · doi:10.1007/s11102-008-0114-6 · Cited by 35
Clinical Utility of Mifepristone: Apprising the Expanding Horizons
Karena, Z. V., Shah, H., Vaghela, H., Chauhan, K., Desai, P. K., & Chitalwala, A. R. (2022) · Cureus · doi:10.7759/cureus.28318 · Cited by 27
Antiglucocorticoid and related treatments for psychosis
Garner, B., Phillips, L. J., Bendall, S., & Hetrick, S. E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006995.pub2 · Cited by 27
Psychiatric outcomes following medical and surgical abortion
Sit, D. K. Y., Rothschild, A. J., Creinin, M. D., Hanusa, B. H., & Wisner, K. L. (2006) · Human Reproduction · doi:10.1093/humrep/del450 · Cited by 33
“Therefore, mifepristone may have novel psychotropic properties related to its biological actions on GC receptors (Gold et al., 2002; Flores et al., 2006).”
RU486 Mitigates Hippocampal Pathology Following Status Epilepticus
Wulsin, A. C., Herman, J. P., & Danzer, S. C. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00214 · Cited by 26
Neuropharmacologic Studies on the Brain Serotonin1A Receptor Using the Selective Agonist Osemozotan
Matsuda, T. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00645 · Cited by 27
Psychotic Major Depression: A Benefit-Risk Assessment of Treatment Options
Tyrka, A. R., Price, L. H., Mello, M. F., Mello, A. F., & Carpenter, L. L. (2006) · Drug Safety · doi:10.2165/00002018-200629060-00003 · Cited by 28
Gómez-Lázaro, E., Garmendia, L., Beitia, G., Pérez-Tejada, J., Azpiroz, A., & Arregi, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.019 · Cited by 30
“Thus, in this case, the blocking of GRs may constitute a more appropriate mechanism for inducing an antidepressant effect (DeBattista et al., 2006; Flores et al., 2006; Young et al., 2004).”
Neural Signaling of Cortisol, Childhood Emotional Abuse, and Depression-Related Memory Bias
Abercrombie, H. C., Frost, C. P., Walsh, E. C., Hoks, R. M., Cornejo, M. D., Sampe, M., Gaffey, A. E., Plante, D. T., Ladd, C. O., & Birn, R. M. (2017) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.11.005 · Cited by 29
Sommer, O., Aug, R. L., Schmidt, A. J., Heiser, P., Schulz, E., Vedder, H., & Clement, H.-W. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00501 · Cited by 23
“(73) suggested that this might be responsible for their effectivity (17).”
BackgroundHaass‐Koffler, C. L., Magill, M., Cannella, N., Brown, J. C., Aoun, E. G., Cioe, P. A., Sinha, R., Swift, R. M., Ciccocioppo, R., & Leggio, L. (2023) · Addiction Biology · doi:10.1111/adb.13288 · Cited by 22
Beckley, E. H., Scibelli, A. C., & Finn, D. A. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.11.004 · Cited by 20
“However, there is considerable interest in using mifepristone to treat some forms of depression (e.g., Benagiano et al., 2008b; Flores et al., 2006), stemming from the fact that it is also a glucocorticoid receptor antagonist (Attardi et al.”
BackgroundSrikumar, B. N., Paschapur, M. S., Kalidindi, N., Adepu, B., Das, M. L., Sreedhara, M. V., Kuchibhotla, V. K., Pieschl, R. L., Li, Y.-W., Ega, D. S. P., et al. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.003 · Cited by 21
“Further, the ACTH model has the potential to be used to screen antidepressants that are useful in the treatment of psychotic depression, where HPA axis function is altered (Flores et al., 2006).”
BackgroundAntiglucocorticoids, Neurogenesis and Depression
Fitzsimons, C. P., van Hooijdonk, L. W. A., Morrow, J. A., Peeters, B. W. M. M., Hamilton, N. M., Craighead, M. W., & Vreugdenhil, E. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787316001 · Cited by 22
“The short time frame for the cellular effects of mifepristone on neurogenesis after chronic stress parallels its fast acting effects in clinical studies where 4 days of treatment was reported to relieve symptoms of psychotic depression [62, 65, 66].”
BackgroundPsychotic Depression—Beyond the Antidepressant/Antipsychotic Combination
Nelson, E. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0315-6 · Cited by 18
Development of New Psychopharmacological Agents for Depression and Anxiety
Schatzberg, A. F. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.009 · Cited by 19
Self-citationLecca, S., Trusel, M., & Mameli, M. (2016) · Synapse · doi:10.1002/syn.21948 · Cited by 20
Magnesium and major depression
Eby, G. A., Eby, K. L., & Murck, H. (2011) · University of Adelaide Press eBooks · doi:10.1017/upo9780987073051.024 · Cited by 20
The Role of the Adrenal–Gut–Brain Axis on Comorbid Depressive Disorder Development in Diabetes
Mázala-de-Oliveira, T., da Silva, B. P. B., Campello‐Costa, P., & Carvalho, V. F. (2023) · Biomolecules · doi:10.3390/biom13101504 · Cited by 20
“For instance, several studies have shown an imbalance in the Firmicutes/Bacteroidetes ratio in patients with MDD [113–116].”
ResultTargeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
“Based on the results, the authors were able to conclude that a 7-day course of mifepristone followed by usual treatment appears to be effective and well tolerated in the treatment of psychosis in PMD.”
BackgroundInfluentialCortisol trajectory, melancholia, and response to electroconvulsive therapy
Mickey, B. J., Ginsburg, Y., Sitzmann, A. F., Grayhack, C., Sen, S., Kirschbaum, C., Maixner, D. F., & Abelson, J. L. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.05.007 · Cited by 20
“Beyond the specific application to ECT, cortisol trajectory might also prove useful for personalized targeting of novel therapeutics like the anti-glucocorticoid agent mifepristone (Flores et al., 2006) or other established pharmacologic and psychosocial interventions.”
BackgroundPharmacological treatment for psychotic depression
Wijkstra, J., Lijmer, J. G., Burger, H., Geddes, J. R., & Nolen, W. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004044.pub3 · Cited by 19
Matsumoto, Y., Niwa, M., Mouri, A., Noda, Y., Fukushima, T., Ozaki, N., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4704-8 · Cited by 15
“A glucocorticoid receptor (GR) antagonist, RU486 (mifepristone), is uniquely beneficial in human psychotic depression (Flores et al. 2006).”
Cryan, J. F., Sánchez, C., Dinan, T. G., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00007-2 · Cited by 17
Wedekind, D., Preiss, B., Cohrs, S., Rüther, E., Huether, G., & Adler, L. (2007) · Neuropsychobiology · doi:10.1159/000112953 · Cited by 17
Current and emerging somatic treatment strategies in psychotic major depression
Dannon, P. N., Lowengrub, K., Gonopolski, Y., & Kotler, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.1.73 · Cited by 16
Mifepristone in Psychotic Depression?
Carroll, B. J., & Rubín, R. T. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.032 · Cited by 15
Is Mifepristone Useful in Psychotic Depression?
Carroll, B. J., & Rubín, R. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301170 · Cited by 14
Issues encountered in recent attempts to develop novel antidepressant agents
Schatzberg, A. F. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12716 · Cited by 12
Self-citationClark, R. D., Ray, N. C., Blaney, P. M., Crackett, P. H., Hurley, C. A., Williams, K. R., Dyke, H. J., Clark, D. E., Lockey, P. M., Devos, R., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.055 · Cited by 12
Golier, J. A., Li, X., Bizien, M. D., Hurley, R. A., Bechard, B. W., Kimbrell, T. A., Flory, J. D., Baker, D. G., Yehuda, R., & Reda, D. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10223 · Cited by 12
Yuen, K. C. J., Moraitis, A. G., & Nguyen, D. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1097 · Cited by 12
Dosing and Monitoring: Children and Adolescents.
Hirsch, G. S. (2018) · Europe PMC (PubMed Central) · Cited by 11
Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders
Roat-Shumway, S., Wroolie, T., Watson, K. T., Schatzberg, A. F., & Rasgon, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.014 · Cited by 10
Self-citationLinsen, F., Broeder, C. E., Sep, M. S. C., Verhoeven, J. E., Bet, P. M., Penninx, B. W. J. H., Meijer, O. C., & Vinkers, C. H. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04830-9 · Cited by 11
Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 12
Developing selectively nonselective drugs for treating CNS disorders
Gray, J. A., & Roth, B. L. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.11.009 · Cited by 11
Multiple Clinical Indications of Mifepristone: A Systematic Review
Mathew, S. A., Ticsa, M. S., Qadir, S., Rezene, A., & Khanna, D. (2023) · Cureus · doi:10.7759/cureus.48372 · Cited by 14
“Moreover, when researchers looked further into the use of mifepristone in psychotic depression disorders, they discovered a correlation between higher plasma levels of mifepristone and a reduction in psychotic symptoms [7].”
BackgroundInfluentialFresh approaches to antidepressant drug discovery
Anacker, C. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.892071 · Cited by 9
“Clinically, brief administration of the pharmacological GR antagonist, mifepristone (RU486), for 4 days has shown some effectiveness in relieving symptoms of psychotic depression [40,41].”
BackgroundEffects of RU486 treatment after single prolonged stress depend on the post-stress interval
Ding, J., Chen, X., da Silva, M. S., Lingeman, J., Han, F., & Meijer, O. C. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103541 · Cited by 8
“Earlier RU486 has been studied in clinical trials for treatment of depression and stress disorders (Flores et al., 2006; Taubenfeld et al., 2009).”
BackgroundUban, K. A., Bodnar, T. S., Butts, K. A., Sliwowska, J. H., Comeau, W. L., & Weinberg, J. (2010) · Health care and disease management · doi:10.1002/9783527632510.ch5 · Cited by 11
Affective Disorders: Depression and Bipolar Disorders
Blackburn, T. P., & Wasley, J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00163-2 · Cited by 8
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work
Milo, T., Halber, S. N., Raz, M., Danan, D., Mayo, A., & Alon, U. S. (2025) · Molecular Systems Biology · doi:10.1038/s44320-024-00083-0 · Cited by 8
Mifepristone blocks the anxiolytic- and antidepressant-like effects of allopregnanolone in male rats
Choudhary, D., Sasibhushana, R. B., Rao, B. S. S., & Srikumar, B. N. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2153047 · Cited by 7
“…that brief treatment with mifepristone could ameliorate mood and cognition [ 17 ] and an improvement was seen in psychotic depression also [ 18–20 ]. a study [19 ] in patients with depression and psychoses showed substantial resolution after six days treatment with mifepristone. in the…”
Che, A. M., Gomez, R. G., Keller, J., Lembke, A., Tennakoon, L., Cohen, G. H., & Schatzberg, A. F. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.12.001 · Cited by 6
“Forty-nine (21 males and 28 female) PMD participants were recruited by inpatient and outpatient facilities at Stanford or were self-referred by online and community advertisements (Flores et al., 2006).”
BackgroundInfluentialSelf-citationReply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment
Keller, J., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301171 · Cited by 7
“Ohayon and Schatzberg (2002) previously reported that psychotic symptoms can and do occur in patients with less severe depressive symptoms.”
BackgroundSelf-citationNguyen, D., & Mizne, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0621-9 · Cited by 5
“Similar increases in ACTH and cortisol have been observed with mifepristone administration in other healthy (non-CS) populations [12].”
ResultAntiglucocorticoid treatments for mood disorders
Gallagher, P., Malik, N., Newham, J. J., Young, A. H., Ferrier, I. N., & Mackin, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005168.pub3 · Cited by 5
Scholl, J. L., Solanki, R. R., Watt, M. J., Renner, K. J., & Forster, G. L. (2022) · Brain Research · doi:10.1016/j.brainres.2022.148189 · Cited by 4
Chapter 5.7 Adrenal steroids and episodic memory: relevance to mood disorders
Alhaj, H. A., & McAllister-Williams, H. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00232-4 · Cited by 6
Neurobiologische Korrelate der Psychotherapie bei Depression
Jauch‐Chara, K., & Hohagen, F. (2009) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.57.2.105 · Cited by 5
Modulation of HPA Axis Function for Treatment of Mood Disorders
Brothers, S. P., Wahlestedt, C., & Nemeroff, C. B. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00276 · Cited by 4
Zhong, C., Lu, Y., Li, Y., Xie, H., Zhou, G., & Jia, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114416 · Cited by 3
Mifepristone modulates serotonin transporter function
Li, C., Shan, L., Jiang, H., Li, X., Wei, L., & Li, D. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.130112 · Cited by 3
“RU-486 has also been shown to relieve the symptoms of psychotic depression after a brief period of 4–8 days (Flores et al., 2006; Blasey et al., 2009).”
BackgroundInfluentialPharmacotherapy for Psychotic Depression
Howland, R. H. (2006) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20061201-08 · Cited by 3
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 5
Abayomi, O., Amato, D., Bailey, C. C., Bitanihirwe, B. K. Y., Bowen, L., Burshtein, S., Cullen, A. E., Fusté, M., Herrmann, A. P., Khodaie, B., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.032 · Cited by 6
“Similarly, in a human trial, mifepristone has been shown to be effective in the treatment of psychotic depression by possibly re-regulation of the HPA axis (Flores et al., 2006).”
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as02 · Cited by 3
Llorente, M. D., & Malphurs, J. E. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-850-8_14 · Cited by 2
Genetic Transmission of Behavior and Its Neuroendocrine Correlates
Hambsch, B., Landgraf, R., Czibere, L., & Touma, C. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00084-x · Cited by 6
Targeting the HPA axis in major depression: does it work?
Claes, S. J. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005983 · Cited by 4
Holsboer‐Trachsler, E., & Holsboer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_53 · Cited by 2
Rubín, R. T., & Carroll, B. J. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.10.009 · Cited by 2
DeBattista, C., & Belanoff, J. K. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.10.007 · Cited by 2
The Glucocorticoid Antagonist RU-486 Suppresses HIV Infectivity and Replication
Benton, T. D., Lynch, K. G., Dubé, B., Gettes, D. R., Tustin, N. B., Metzger, D. S., Blume, J., Douglas, S. D., & Evans, D. L. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12060147 · Cited by 2
The Etiology of Depression and the Therapeutic Implications
Akiki, T. J. (2014) · Journal of medical research/The journal of medical research · Cited by 2
Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
MacKinnon, D. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch50 · Cited by 3
Anti‐Inflammatory Glucocorticoids
Avery, M. A., & Chittiboyina, A. G. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc192 · Cited by 2
Maddalena, A. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3916 · Cited by 1
Lucassen, P. J., Fitzsimons, C. P., Vreugdenhil, E., Hu, P., Oomen, C. A., Revsin, Y., Joëls, M., & de Kloet, E. R. (2011) · Wiley eBooks · doi:10.1002/9783527633968.ch6 · Cited by 1
Gene Therapy and Protection from Stress-Induced Brain Damage
Sapolsky, R. M. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00094-2 · Cited by 2
Neurobiologic Foundations of Mood Disorders
Polan, H. J., Duman, R. S., & Schatzberg, A. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch21
Self-citationIntroductory and Basic Aspects
Romero, L. I., Montero, A., Fernández, B., & Vela, J. M. (2007) · Wiley eBooks · doi:10.1002/9783527619337.ch1
Gouzien, C., Doumy, O., & Aouizerate, B. (2015) · doi:10.1016/b978-2-294-73908-8.00004-5 · Cited by 1
Meeting Highlights on Mood Disorders: The 3rd Annual Chair Summit
Johnson, M. D., Binford, S. H., Ansted, C. J., & Kennedy, R. S. (2011) · Health Outcomes Research in Medicine · doi:10.1016/j.ehrm.2011.07.007
Stress, emotional learning and AMPA receptors: from behavior to molecule
Mengyuan, Z. (2011) · UvA-DARE (University of Amsterdam)
Dell’Osso, B. M., Bareggi, S. R., Palazzo, M. C., Camuri, G., Bortolussi, S., & Altamura, A. C. (2010)
Glucocorticoid modulation of the mesocortical dopamine system and aspects of executive function
Butts, K. A. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0073693
“Similarly, short-term intervention with RU-38486 has also proven to be beneficial in the treatment for psychotic depression (Flores et al., 2006).”
BackgroundComplementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression
Menke, A., Dusi, N., & Brambilla, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-27040-1_5
“In small samples, mifepristone could actually attenuate depressive symptoms signifi cantly better than placebo treatment [ 6 , 27 ].”
The neuroendocrinology of stress in the pathophysiology of bipolar disorders
Young, A. H., & Colasanti, A. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107477278.009
Effects of early life stress: Opportunities for pharmacological intervention
Loi, M. (2016) · Utrecht University Repository (Utrecht University)
Chopra, K. K. (2013) · TSpace (University of Toronto)
Regulation of the Rat Hepatic NADPH-cytochrome P450 Oxidoreductase by Glucocorticoids
Vonk, A. (2014) · TSpace (University of Toronto)
Anti‐Inflammatory Glucocorticoids
Avery, M. A., & Chittiboyina, A. G. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc192.pub2
Sullivan, R. M., & Raineki, C. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733419583.793550327
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as02
Buinho, A., Soares, F. R., & Rema, J. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00329-6
“In the mifepristone group, patients who responded clinically to the drug also showed a decrease in mean ACTH levels between the hours 1800 to 0100 compared to those who didn’t [16].”
Yan, Y., Zhu, X., Dong, P., Liu, C., Lu, L., Zeng, L., Chen, G., Meng, X., & Liu, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1479205
Emerging Therapeutic Approaches and Drugs for Anxiety and Related Disorders
Kumar, V., Nahari, S. T. M. A. A., Singh, S. K., Kumar, A., Wadhwa, P. K., Duggal, N., & Tewari, D. (2025) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_47_25
Major, G. S., Timpani, C. A., Russell, A. P., Rybalka, E., & Lindsay, A. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111766
The effects of childhood trauma on neurocognitive functioning in Bipolar Disorder type I patients
Stessen, L. E. R. M. (2014) · Utrecht University Repository (Utrecht University)
Linsen, F., Broeder, C. E., Sep, M. S. C., Verhoeven, J. E., Bet, P. M., Penninx, B. W. J. H., Meijer, O. C., & Vinkers, C. H. (2024) · Figshare · doi:10.6084/m9.figshare.26588757
Metadata
- Authors
- Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F.
- Affiliations
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Flores, Benjamin H
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-14
- Volume
- 31
- Issue
- 3
- Pages
- 628-636
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2081535802
- Cited by
- 203
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 13 · 2012: 11
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (MH50604)
- National Institute of Mental Health (R0-1MH50604, MH-47573, R01MH050604, R01 MH 47573, R01MH047573, T32MH019938)
- National Center for Research Resources (M01RR000070)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, psychotic depression, glucocorticoid receptor antagonist, hypothalamic-pituitary-adrenal axis, cortisol, ACTH, depression treatment
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Psychiatric Status Rating Scales, Receptors, Glucocorticoid, Sex Characteristics, Mifepristone, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.